321 related articles for article (PubMed ID: 24595801)
1. Accuracy of CT staging of locally advanced gastric cancer after neoadjuvant chemotherapy: cohort evaluation within a randomized phase II study.
Yoshikawa T; Tanabe K; Nishikawa K; Ito Y; Matsui T; Kimura Y; Hasegawa S; Aoyama T; Hayashi T; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S385-9. PubMed ID: 24595801
[TBL] [Abstract][Full Text] [Related]
2. Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial.
Yoshikawa T; Tanabe K; Nishikawa K; Ito Y; Matsui T; Kimura Y; Hirabayashi N; Mikata S; Iwahashi M; Fukushima R; Takiguchi N; Miyashiro I; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J
Ann Surg Oncol; 2014 Jan; 21(1):213-9. PubMed ID: 23838904
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer.
Inoue K; Nakane Y; Kogire M; Fujitani K; Kimura Y; Imamura H; Tamura S; Okano S; Kwon AH; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
Eur J Surg Oncol; 2012 Feb; 38(2):143-9. PubMed ID: 22154885
[TBL] [Abstract][Full Text] [Related]
4. Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer.
Yoshikawa T; Morita S; Tanabe K; Nishikawa K; Ito Y; Matsui T; Fujitani K; Kimura Y; Fujita J; Aoyama T; Hayashi T; Cho H; Tsuburaya A; Miyashita Y; Sakamoto J
Eur J Cancer; 2016 Jul; 62():103-11. PubMed ID: 27244537
[TBL] [Abstract][Full Text] [Related]
5. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.
Lorenzen S; Blank S; Lordick F; Siewert JR; Ott K
Ann Surg Oncol; 2012 Jul; 19(7):2119-27. PubMed ID: 22395980
[TBL] [Abstract][Full Text] [Related]
6. A comparison of multimodality treatment: two and four courses of neoadjuvant chemotherapy using S-1/CDDP or S-1/CDDP/docetaxel followed by surgery and S-1 adjuvant chemotherapy for macroscopically resectable serosa-positive gastric cancer: a randomized phase II trial (COMPASS-D trial).
Yoshikawa T; Taguri M; Sakuramoto S; Kunisaki C; Fukunaga T; Ito S; Cho H; Tanabe K; Nishikawa K; Matsui T; Morita S; Tsuburaya A
Jpn J Clin Oncol; 2012 Jan; 42(1):74-7. PubMed ID: 22102736
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer.
Fukuchi M; Ishiguro T; Ogata K; Suzuki O; Kumagai Y; Ishibashi K; Ishida H; Kuwano H; Mochiki E
Ann Surg Oncol; 2015 Oct; 22(11):3618-24. PubMed ID: 25663597
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of docetaxel and S-1 (DS) as neoadjuvant chemotherapy for clinical stage III resectable gastric cancer.
Oki E; Emi Y; Kusumoto T; Sakaguchi Y; Yamamoto M; Sadanaga N; Shimokawa M; Yamanaka T; Saeki H; Morita M; Takahashi I; Hirabayashi N; Sakai K; Orita H; Aishima S; Kakeji Y; Yamaguchi K; Yoshida K; Baba H; Maehara Y
Ann Surg Oncol; 2014 Jul; 21(7):2340-6. PubMed ID: 24604583
[TBL] [Abstract][Full Text] [Related]
10. A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS).
Yoshikawa T; Tsuburaya A; Morita S; Kodera Y; Ito S; Cho H; Miyashita Y; Sakamoto J
Jpn J Clin Oncol; 2010 Apr; 40(4):369-72. PubMed ID: 20299499
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.
Ito S; Sano T; Mizusawa J; Takahari D; Katayama H; Katai H; Kawashima Y; Kinoshita T; Terashima M; Nashimoto A; Nakamori M; Onaya H; Sasako M
Gastric Cancer; 2017 Mar; 20(2):322-331. PubMed ID: 27299887
[TBL] [Abstract][Full Text] [Related]
12. Low creatinine clearance is a risk factor for D2 gastrectomy after neoadjuvant chemotherapy.
Hayashi T; Aoyama T; Tanabe K; Nishikawa K; Ito Y; Ogata T; Cho H; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Yoshikawa T
Ann Surg Oncol; 2014 Sep; 21(9):3015-22. PubMed ID: 24715213
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer.
Shinkai M; Imano M; Chiba Y; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
J Surg Oncol; 2019 Jan; 119(1):56-63. PubMed ID: 30444009
[TBL] [Abstract][Full Text] [Related]
14. [A patient with advanced gastric cancer who responded to neoadjuvant S-1 plus cisplatin chemotherapy].
Tanaka H; Doi K; Ogata K; Inoue K; Sugiyama S; Iwatsuki M; Furuhashi S; Ogawa K; Takamori H
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2207-9. PubMed ID: 24394061
[TBL] [Abstract][Full Text] [Related]
15. [Neoadjuvant chemotherapy with combined S-1 plus weekly low-dose cisplatin followed by surgical resection for advanced gastric cancer].
Isobe T; Hashimoto K; Kizaki J; Miyagi M; Aoyagi K; Koufuji K; Shirouzu K
Gan To Kagaku Ryoho; 2013 Oct; 40(10):1331-5. PubMed ID: 24105055
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer.
Barone C; Cassano A; Pozzo C; D'Ugo D; Schinzari G; Persiani R; Basso M; Brunetti IM; Longo R; Picciocchi A
Oncology; 2004; 67(1):48-53. PubMed ID: 15459495
[TBL] [Abstract][Full Text] [Related]
17. [Neoadjuvant chemotherapy using TS-1 and CDDP against large type 3/Type 4/Bulky N 2 advanced gastric cancer].
Tanemura H; Oshita H; Kanno A; Kusakabe M; Hatoh T; Yamada M; Adachi T; Nishio K; Saito S; Tomita E; Sugiyama A; Yamada T
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2079-85. PubMed ID: 16352932
[TBL] [Abstract][Full Text] [Related]
18. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03.
Okabe H; Hata H; Ueda S; Zaima M; Tokuka A; Yoshimura T; Ota S; Kinjo Y; Yoshimura K; Sakai Y;
J Surg Oncol; 2016 Jan; 113(1):36-41. PubMed ID: 26604064
[TBL] [Abstract][Full Text] [Related]
20. [A successfully treated case of type 4 gastric cancer with intraperitoneal free cancer cells undergoing a curative resection followed by neoadjuvant chemotherapy with S-1 plus cisplatin].
Koizumi S; Iwasaki Y; Ohashi M; Iwanaga T; Ohinata R; Takahashi K; Yamaguchi T; Matsumoto H; Nakano D; Tateishi Y
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2464-6. PubMed ID: 21224607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
